Structural Heart Disease

Structural heart diseases include any issues preventing normal cardiovascular function due to damage or alteration to the anatomical components of the heart. This is caused by aging, advanced atherosclerosis, calcification, tissue degeneration, congenital heart defects and heart failure. The most commonly treated areas are the heart valves, in particular the mitral and aortic valves. These can be replaced through open heart surgery or using cath lab-based transcatheter valves or repairs to eliminate regurgitation due to faulty valve leaflets. This includes transcatheter aortic valve replacement (TAVR). Other common procedures include left atrial appendage (LAA) occlusion and closing congenital holes in the heart, such as PFO and ASD. A growing area includes transcatheter mitral repair or replacement and transcatheter tricuspid valve repair and replacement.

Robotic mitral valve repair linked to benefits for elderly patients
Robotic and traditional mitral valve repair surgeries are mostly associated with similar outcomes when treating elderly patients. In some ways, however, robotic procedures may be preferred.
Vendor payments not responsible for rising popularity of LAAO procedures
Consulting fees and other vendor payments do not appear to be directly influencing U.S. physicians to implant more Watchman devices. Researcher Alexander Kolomaya, MD, discussed his team's findings on this topic.
Self-expanding TAVR valves deliver outcomes and durability comparable to surgery after 5 years
Michael Reardon, MD, detailed five-year data out of ACC.25 that found Medtronic's Evolut TAVR platform performs as well as SAVR—and even better in some ways.
Underweight TAVR patients face higher mortality risk—obesity makes no significant impact
Reviewing data from more than 6,000 patients, researchers found little evidence of the "obesity paradox" observed elsewhere. Underweight TAVR patients, however, may face some significant long-term risks.
SCAI pushes for better radiation protection in cath labs
Society of Cardiovascular Angiography and Interventions President James Hermiller, Jr., MD, explains SCAI's push for wider adoption of new, innovative cath lab radiation protection technology to reduce radiation exposure and the need for lead aprons.

Underdiagnosed and undertreated: How cardiologists and primary care physicians are working together to identify patients with severe aortic stenosis

Sponsored by Medtronic

Updates about transcatheter aortic valve replacement (TAVR) are always big news, but the new five-year data from the CoreValve™ US Pivotal and SURTAVI trials came as a welcome surprise to many cardiologists.

A TAVR procedure being performed at Northwestern Medicine in Chicago. These structural heart procedures require a team approach.

Earlier interventions may boost survival when TAVR patients experience a stroke

New research in JACC: Cardiovascular Interventions suggests improved collaborations between cardiologists and neurologists could help TAVR patients live longer after a periprocedural stroke.

CT imaging showing the congenital heart defect of left heart hypoplastic syndrome.

VIDEO: Congenital heart imaging with cardiac CT

As the population of patients with adult congenital heart disease grows, they are presenting to adult cardiology clinics and being imaged with CT. Many also do not have access or cannot be imaged by MRI, said Renee Bullock-Palmer, MD.

The Medtronic Intrepid transcatheter mitral valve replacement (TMVR) system performed well in two studies presendted at TCT 2022. #TCT #TCT22 #TCT2022 #TMVR

Intrepid transcatheter mitral valve pilot study shows positive 3-year outcomes

New data on the Medtronic Intrepid transcatheter mitral valve replacement system from the Intrepid Pilot Study and Intermediate-Term Outcomes of the Intrepid Early Feasibility Study, were presented at the 2022 Transcatheter Cardiovascular Therapeutics (TCT) conference.

Impella Heart Pump Abiomed RECOVER IV RCT cardiogenic shock

Regulatory Roundup: FDA clears AI model for RV/LV ratios, approves calcium-blocking TAVR valve and much more

Read our review of some of the biggest FDA-related stories that have hit cardiology in the last month, including news from Viz.ai, Edwards Lifesciences, Abiomed and Medtronic.

Medtronic launches Evolut FX TAVR system aortic stenosis

Medtronic launches Evolut FX TAVR system for severe aortic stenosis

This is the fourth device in Medtronic's Evolut TAVR platform. The self-expanding valve gained FDA approval in 2021 for the treatment of high- and low-risk patients presenting with symptomatic severe aortic stenosis.

The Pascal transcatheter mitral valve repair system. Similar to the latest version of the MitraClip, the Pascal can operate each leaflet independently to grasp the mitral valve leaflets. Results of the CLASP IID trial at #TCT2022.

Pascal transcatheter mitral repair device performs as well as MitraClip in late-breaking CLASP IID Trial

Comparison between transcatheter edge-to-edge repair (TEER) devices found Pascal was non-inferior compared with MitraClip in the CLASP IID pivotal trial.

Structural Heart Disease

Robotic mitral valve repair linked to benefits for elderly patients

Vendor payments not responsible for rising popularity of LAAO procedures

Self-expanding TAVR valves deliver outcomes and durability comparable to surgery after 5 years

Underweight TAVR patients face higher mortality risk—obesity makes no significant impact

SCAI pushes for better radiation protection in cath labs